Digostics Raises $0 To Scale At-Home OGTT Testing And Throughput

Digostics has raised an undisclosed amount. Digostics offers the world's first and only alternative to in-clinic oral glucose tolerance testing (OGTT) by enabling this diabetes test to be performed at home. The company positions its approach as a response to a persistent detection gap: roughly half of adults living with diabetes remain undiagnosed, a shortfall that the company says requires an immediate step-change in how testing is performed. Digostics frames its solution around simplified testing, increased patient throughput, and improved outcomes through more accessible OGTT. The funding announcement is significant because it signals continued attention to diagnostic innovation in a condition with substantial population health consequences. Bringing OGTT out of the clinic has the potential to change where and how patients are screened, which could influence diagnosis timelines and service capacity. For health systems that currently rely on in-clinic testing to identify glycemic disorders, an at-home alternative represents a different operational model that could affect referral and follow-up pathways. Digostics has not disclosed specific plans for how the proceeds will be allocated. The company did not provide details on timeline, regulatory milestones, clinical deployments, or other operational uses tied to the round. External observers and potential partners will likely look for subsequent updates that clarify whether the capital will support broader distribution, additional validation work, or integration with clinical workflows, but those purposes have not been specified by the company at the time of the announcement. Looking ahead, the impact of Digostics’ at-home OGTT will depend on demonstration of clinical reliability, regulatory acceptance, and uptake by clinicians and patients. Future progress reports on validation, partnerships, and deployment will be key indicators of whether the technology can materially reduce the proportion of undiagnosed diabetes and alter standard testing practices.